Today: 2 June 2026
Browse Category

Pharmaceuticals 11 May 2026 - 31 May 2026

Pfizer Stock Had a Quiet Week. Its Cancer Pipeline Just Got Loud

Pfizer Stock Had a Quiet Week. Its Cancer Pipeline Just Got Loud

Pfizer faces a key market test Monday after unveiling new cancer drug data at ASCO and a China partnership worth up to $10.5 billion. Friday’s close: $26.18, up 0.15%. Braftovi nearly doubled progression-free survival in metastatic colorectal cancer; Talzenna plus Xtandi cut prostate cancer risk by 52%. Seven-year Lorbrena data showed 55% of lung cancer patients alive without progression. Innovent deal flagged for early-stage risk.
31 May 2026
·
Eli Lilly’s $20 Billion M&A Push Moves Into Vaccines

Eli Lilly’s $20 Billion M&A Push Moves Into Vaccines

Eli Lilly will acquire Curevo Inc., LimmaTech Biologics AG, and Vaccine Company Inc. for up to $3.83 billion in cash, gaining vaccine programs for shingles, staph infections, and Epstein-Barr virus. Shares rose about 5% after news of the deals and broader coverage for Zepbound and Foundayo. Curevo shareholders may receive up to $1.5 billion, LimmaTech $780 million, and Vaccine Company $1.55 billion.
28 May 2026
···
Hoth Therapeutics Changes Name to Rocket One, RKTO Stock Moves

Hoth Therapeutics Changes Name to Rocket One, RKTO Stock Moves

Rocket One Inc., formerly Hoth Therapeutics, began trading under the new Nasdaq ticker RKTO Thursday after a rebrand and pivot to AI chip technology for space. Shares jumped 47% pre-market to $1.999, following a 92% surge in the previous session. The company retains its biotech pipeline under a subsidiary but highlights early-stage tech, capital needs, and going-concern risks in filings.
28 May 2026
··
Jupiter Neurosciences Stock Swings on $100M MDMA Pact, $2M Equity Sale

Jupiter Neurosciences Stock Swings on $100M MDMA Pact, $2M Equity Sale

Jupiter Neurosciences shares fell 37% to $0.205 Wednesday after announcing a proposed U.S. licensing deal for PharmAla Biotech’s MDMA-based ALA-002 and a $2 million stock offering. Trading volume topped 230 million shares. The licensing agreement is non-binding, with a potential value over $100 million, and gives Jupiter 90 days to finalize terms. Jupiter reported a $2.06 million Q1 net loss and $2.36 million in cash.
21 May 2026
···
Immunovant Stock Surges 35% After Arthritis Drug Data: Why Wall Street Is Repricing IMVT

Immunovant Stock Surges 35% After Arthritis Drug Data: Why Wall Street Is Repricing IMVT

Immunovant shares jumped 35.3% to $35.56 after reporting 16-week data showing its drug IMVT-1402 produced ACR20, ACR50, and ACR70 response rates of 72.7%, 54.5%, and 35.8% in difficult-to-treat rheumatoid arthritis. Roivant Sciences, its majority owner, rose 14.9%. No new safety signals were reported. The trial enrolled 170 patients, most of whom had failed two prior advanced therapies.
20 May 2026
···
InMed Pharmaceuticals (INM) Stock Doubled on Mentari Merger — Why the Rally Is Already Being Tested

InMed Pharmaceuticals (INM) Stock Doubled on Mentari Merger — Why the Rally Is Already Being Tested

InMed Pharmaceuticals shares fell 14.4% to $1.37 in early pre-market trading Wednesday, after surging 135% Tuesday on news of an all-stock merger with Mentari Therapeutics and a planned $290 million private placement. Pre-merger InMed shareholders are expected to own about 1.51% of the combined company, which will operate as Mentari Therapeutics and focus on migraine drug development.
20 May 2026
··
Relay Therapeutics Shares Rise In Pre-Market Ahead Of Key Drug Update

Relay Therapeutics Shares Rise In Pre-Market Ahead Of Key Drug Update

Relay Therapeutics shares jumped 11.3% to $13.47 in premarket trading Tuesday after reporting a 60% volumetric response rate in 20 evaluable patients from its Phase 2 trial of zovegalisib for vascular anomalies. The company said 95% of patients saw some lesion reduction at 12 weeks. No patients discontinued due to adverse events. The regular Nasdaq session was set to open at 9:30 a.m. ET.
19 May 2026
··
Regeneron Opens Lower After Cancer Trial Setback

Regeneron Opens Lower After Cancer Trial Setback

Regeneron shares dropped 11.8% in premarket trading Monday after its melanoma drug combo failed to meet the main goal in a late-stage trial. The high-dose fianlimab and cemiplimab combination showed a median progression-free survival of 11.5 months versus 6.4 months for Merck’s Keytruda, but missed statistical significance. Citi downgraded the stock and cut its price target to $700. Regeneron shares closed Friday at $698.25.
18 May 2026
··
Pfizer Faces Busy Week After Friday’s Drop

Pfizer Faces Busy Week After Friday’s Drop

Pfizer shares closed at $25.33 Friday, down 1.63%, underperforming the S&P 500, which fell 1.24% but still posted a weekly gain. The company reaffirmed its 2026 revenue and earnings guidance after first-quarter revenue rose 5% to $14.45 billion. Investors remain cautious, citing competitive pressure from Eli Lilly and uncertainty over Pfizer’s pipeline. U.S. markets reopen Monday.
17 May 2026
···
Pfizer Inc Looks to India, but Investors Hold Off

Pfizer Inc Looks to India, but Investors Hold Off

Pfizer is increasing investment in India for cancer drugs, obesity treatments, and vaccines as it seeks growth beyond COVID-era sales. The company reported Q1 revenue of $14.5 billion, up 5%, but expects a $1.5 billion hit this year from generic competition. Shares fell 1.8% to $25.29 in New York trading. In Europe, Pfizer won expanded approval for its hemophilia drug Hympavzi.
15 May 2026
·
REGENXBIO Stock Plunges as Duchenne Gene Therapy Win Runs Into Safety Questions

REGENXBIO Stock Plunges as Duchenne Gene Therapy Win Runs Into Safety Questions

REGENXBIO shares fell 37% to $6.31 after its Duchenne muscular dystrophy gene therapy, RGX-202, met the main goal in a late-stage trial. Investors reacted to two serious adverse events and uncertainty over FDA approval. The company reported 93% of patients showed microdystrophin expression at 12 weeks. REGENXBIO said it will seek accelerated approval and targets a 2027 launch.
14 May 2026
····
Apellis Pharmaceuticals Vanishes From Nasdaq as Biogen’s Rare-Disease Bet Takes Over

Apellis Pharmaceuticals Vanishes From Nasdaq as Biogen’s Rare-Disease Bet Takes Over

Biogen closed its $5.3 billion acquisition of Apellis Pharmaceuticals, making Apellis a wholly owned subsidiary and ending its Nasdaq listing. Apellis shareholders receive $41 per share in cash plus a contingent value right tied to Syfovre sales. Biogen gains Syfovre and Empaveli, which generated $689 million in 2025 revenue. Biogen funded the deal with $2 billion in unsecured term loans.
14 May 2026
···
SELLAS Stock Jumps After AML Trial Moves Two Events From Final Readout

SELLAS Stock Jumps After AML Trial Moves Two Events From Final Readout

SELLAS Life Sciences said its pivotal REGAL leukemia trial has recorded 78 of 80 events needed for final analysis, triggering a rise in after-hours trading. The company reported a first-quarter net loss of $8.4 million but ended March with $107.1 million in cash. Research and development spending increased to $5.1 million. SELLAS expects its cash to fund operations for at least 12 months.
13 May 2026
···
Ernexa Stock’s 58% Jump Shows How Fast a Tiny Biotech Can Reprice on Ovarian-Cancer Hopes

Ernexa Stock’s 58% Jump Shows How Fast a Tiny Biotech Can Reprice on Ovarian-Cancer Hopes

Ernexa Therapeutics shares jumped 58.5% to $11.43 Tuesday after renewed investor focus on its preclinical ovarian-cancer therapy ERNA-101, following a May 11 investor event. Trading volume reached about 18.85 million shares. The company reported $8.3 million in cash as of April 30, less than needed for its 12-month plan, and may use an at-the-market stock sale to raise funds.
12 May 2026
··
Hims & Hers Health Earnings Today: Why One GLP-1 Question Could Move HIMS Stock

Hims & Hers Health Earnings Today: Why One GLP-1 Question Could Move HIMS Stock

Hims & Hers Health reports first-quarter results Monday after the market close, with Wall Street expecting about $617 million in revenue and EPS of 3 to 4 cents. Investors are watching whether its weight-loss business can grow after it stopped broadly marketing compounded GLP-1 drugs and shifted to FDA-approved options from Novo Nordisk. Hims shares closed at $28.46 Friday, rising to $29.07 after hours.
11 May 2026
····
Pfizer Stock Faces a Fresh COVID Patent Overhang as Investors Wait for Its Next Growth Act

Pfizer Stock Faces a Fresh COVID Patent Overhang as Investors Wait for Its Next Growth Act

A Delaware federal judge dismissed Acuitas Therapeutics’ attempt to clear Pfizer and BioNTech’s Comirnaty vaccine from GSK patent claims, citing lack of jurisdiction. The ruling does not address whether Comirnaty infringes GSK’s patents. Pfizer shares last closed at $25.68, down 1.42%. The company reaffirmed 2026 revenue guidance and reported first-quarter revenue of $14.5 billion.
11 May 2026
··
1 2 3 … 41

Latest articles

Hyperscale Data soars 46% after GPUS Bitcoin move draws new attention

Hyperscale Data soars 46% after GPUS Bitcoin move draws new attention

2 June 2026
Hyperscale Data Inc. shares soared 45.9% after the company revealed a $5 million buyback at $0.21 per share, but a recent filing warns up to 43 million new shares could hit the market from convertible notes, threatening dilution and putting pressure on the stock if Bitcoin falls or shares drop below the tender price.
Cisco Stock Jumps as AI Security Push Puts $508 Billion Giant Back in Play

Cisco Stock Jumps as AI Security Push Puts $508 Billion Giant Back in Play

2 June 2026
Cisco shares surged over 5% to $127.54 after unveiling Cloud Control, a new AI-driven platform for managing and securing IT infrastructure, and raising its fiscal 2026 AI order target to $9 billion from $5 billion, signaling strong AI demand beyond chips and boosting investor confidence in Cisco’s growth trajectory.
Oklo Shares Jump as Nuclear Fuel Theme Draws Traders

Oklo Shares Jump as Nuclear Fuel Theme Draws Traders

2 June 2026
Oklo shares surged 8% as investors reacted to U.S. Energy Department talks on surplus plutonium fuel and a looming July deadline for a reactor pilot, with traders betting on advanced nuclear demand from AI and data centers despite ongoing questions about fuel supply, licensing, and first revenue.
IREN Rises After $3.65B AI Backing Puts Focus on Microsoft Commitment

IREN Rises After $3.65B AI Backing Puts Focus on Microsoft Commitment

2 June 2026
IREN Limited soared 3.8% to $67.79 after closing a $3.65 billion investment-grade debt deal to fund GPU purchases for its $9.7 billion Microsoft AI cloud contract, covering 96% of related capital needs; Wall Street turned more bullish, but risks remain if IREN fails to deliver or Microsoft cancels.
Keel Stock Tops $6 Again; Lease Timing Gets Attention After AI Power Bet

Keel Stock Tops $6 Again; Lease Timing Gets Attention After AI Power Bet

2 June 2026
Keel Infrastructure Corp. (KEEL) jumped 2.29% to $6.24 on heavy volume as investors bet on its shift from bitcoin mining to AI data-center power, with a 2.2 GW pipeline and $533 million liquidity, but Q1 revenue fell 22% and net loss hit $145.35 million as the company races to secure key leases and deliver power to AI projects on schedule.
Milbank Raises Big Law Pay Ceiling to $455,000; Rivals React

Milbank Raises Big Law Pay Ceiling to $455,000; Rivals React

2 June 2026
Milbank LLP hiked associate pay up to $455,000, triggering immediate matches from rivals like McDermott Will & Schulte and sparking another round of salary increases among top U.S. law firms, even as rising costs and slower market-wide pay growth pressure firm profitability.
Go toTop